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tion,  FAM222B  (C17orf63) , through exome sequencing of
CCM patients mutation-negative for  CCM1-3 . A yeast 2-hy-
brid screen revealed interactions of FAM222B with the tubu-
lin cytoskeleton and STAMBP which is known to be associat-
ed with microcephaly-capillary malformation syndrome. 
However, a phenotype similar to existing models was not 
found, neither in  fam222bb / fam222ba double mutant zebra-
fish generated by transcription activator-like effector nucle-
ases nor in an in vitro sprouting assay using human umbili-
cal vein endothelial cells transfected with siRNA against 
 FAM222B . These observations led to the assumption that ab-
errant  FAM222B is not involved in the formation of CCMs. 
 © 2016 S. Karger AG, Basel 
 Cerebral cavernous malformations (CCMs) are angio-
graphically occult vascular malformations of the central 
nervous system. With the availability of high-resolution 
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 Abstract 
 Cerebral cavernous malformations (CCMs) are prevalent 
slow-flow vascular lesions which harbour the risk to develop 
intracranial haemorrhages, focal neurological deficits, and 
epileptic seizures. Autosomal dominantly inherited CCMs 
were found to be associated with heterozygous inactivating 
mutations in 3 genes,  CCM1  (KRIT1) ,  CCM2  (MGC4607) , and 
 CCM3  (PDCD10) in 1999, 2003 and 2005, respectively. Despite 
the availability of high-throughput sequencing techniques, 
no further  CCM gene has been published since. Here, we re-
port on the identification of an autosomal dominantly inher-
ited frameshift mutation in a gene of thus far unknown func-
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magnetic resonance imaging (MRI) including gradient-
echo (GRE/T2 * ) and susceptibility-weighted imaging se-
quences, their prevalence has been demonstrated to be 
about 1: 650 among neurologically asymptomatic people 
[Morris et al., 2009]. Familial CCM (MIM 116860, 603284, 
603285) has been assumed to occur in close to 20% of all 
cases and is associated with the development of multiple 
CCMs earlier in life [Fischer et al., 2013]. At-risk family 
members are threatened by the uncertainties of recurrent 
haemorrhages which may cause chronic headache, epi-
lepsy, neurological deficits, and haemorrhagic stroke 
with intrafamilial variability [Fauth et al., 2015].
 Disease penetrance has been reported to be 63, 55, and 
68% for individuals carrying a heterozygous loss-of-func-
tion (LOF) mutation in  CCM1 ,  CCM2 or  CCM3 , respec-
tively [Denier et al., 2006]. Fulminant disease courses with 
hemiparesis during the first years of life have only rarely 
been reported for  CCM1 and  CCM3 mutation carriers. 
However, one third of index patients were children or ad-
olescents when referred for genetic testing [Spiegler et al., 
2014]. The identification of a mutation within one of the 
known  CCM genes in an index case enables predictive ge-
netic testing of further at-risk family members. Most im-
portantly, exclusion of a specific familial mutation relieves 
relatives and their families from unnecessary anxieties 
and medical examinations [Schröder et al., 2014].
 If genetic screening of index cases follows stringent in-
clusion criteria, mutation detection rates are 87% for af-
fected individuals with a positive family history and 57% 
for isolated cases carrying multiple CCMs, the overall 
proportions being 60% for  CCM1 , 18% for  CCM2 , and 
22% for  CCM3 mutations [Spiegler et al., 2014]. While 
some of the isolated mutation-negative cases may be ex-
plained by the occurrence of postzygotic somatic muta-
tions, mutation negativity for the known  CCM1–3 genes 
in familial cases alludes to further genetic heterogeneity. 
In this study, we analysed  FAM222B as a putative candi-
date gene for CCMs and showed that it does not play a 
role in maintaining vascular integrity in vitro and in vivo.
 Materials and Methods 
 Clinical Samples 
 After step-wise sequencing, MLPA and transcript analyses of 
 CCM1–3 had been performed with informed consent according to 
the German Gene Diagnostics Act for all index cases fulfilling the 
established criteria [Stahl et al., 2008; Spiegler et al., 2014]. For the 
4 isolated cases and the father-daughter duo ( fig. 1 A), multiple cav-
ernomas have been verified by MRI. Genomic DNA was isolated 
from peripheral blood leukocytes using standard protocols.
 Whole Exome Sequencing 
 For exome capture, the SOLiD-optimized SureSelect Human 
All Exon 50Mb kit (Agilent Technologies, Santa Clara, Calif., USA) 
was used following the manufacturer’s instructions. Sequencing 
on a SOLiD 5500XL platform (Life Technologies – Thermo Fisher, 
Waltham, Mass., USA) was performed in pools of 4 samples on 2 
lanes of a sequencing slide. On average, mean target sequencing 
depth was 29 and 67% of the exome was covered at least 10 times. 
To verify the results and increase the depth of coverage, target en-
richment and exome sequencing was repeated for all 4 isolated 
probands and the father-daughter duo (mean target sequencing 
depth was 78×). In brief, primary data analysis and variant annota-
tion was done with the bioinformatics pipeline from Radboud 
University Nijmegen Medical Centre (Nijmegen, The Nether-
lands) as described [Neveling et al., 2013]. Using an overlap strat-
egy for index probands I, III–VI ( fig. 1 A) [Hoischen et al., 2010, 
2011], we searched for heterozygous mutations that occur in a sin-
gle gene in at least 2 patients and are expected to disrupt protein 
function (frameshift, stop, and splice mutations). For the father-
daughter duo (probands I and II,  fig. 1 A), a linkage strategy based 
on the suspected autosomal dominant mode of inheritance was 
applied. For both approaches, exclusion of frequent variants in an 
in-house database consisting of 670 exomes as well as frequent 
variants in dbSNP132 (>1%), the exome variant server (EVS, >1%) 
and gonosomes was followed by manual validation of the remain-
ing genes through evaluation of mapped reads, conservation 
scores, expression data, and known phenotypes in mice or ze-
brafish. Following validation of the  FAM222B (ENSEMBL 
ENST00000581407, GenBank NM_018182) frameshift mutation, 
verification analyses were done in a cohort of 15 further CCM pro-
bands that presented with multiple cavernomas on MRI but with-
out a causative mutation in  CCM1–3 . Sanger sequencing was per-
formed on an ABI 3130xl automated sequencer (Applied Biosys-
tems – Thermo Fisher) using the BigDye Terminator Cycle 
Sequencing v3.1 kit (Applied Biosystems – Thermo Fisher). 
 FAM222B primer sequences are available on request.
 Yeast 2-Hybrid Analysis 
 The screen was carried out by Hybrigenics Services SAS, Paris, 
France (http://www.hybrigenics-services.com). To screen a hu-
man fetal brain cDNA library, the cDNA coding for full-length 
human  FAM222B (SC320887, Origene, Rockville, Md., USA) was 
cloned as a C-terminal fusion to the DNA-binding domain of LexA 
into the pB27 vector (N-LexA-FAM222B-C). Yeast cells were 
transfected and 90 million clones (9× coverage of the library com-
plexity) were screened, providing a total of 197 positive clones on 
selective medium supplemented with 1 m M 3-aminotriazole. Pos-
itive clones were sequenced at 5 ′ - and 3 ′ -junctions and the identi-
fication of corresponding interacting proteins in the GenBank da-
tabase was performed on a fully automated basis. Interactions were 
attributed by a confidence score as described [Formstecher et al., 
2005].
 In vivo Studies 
 Zebrafish were maintained in accordance with the approved 
institutional protocols at the Hubrecht Institute. For the genera-
tion of a  fam222bb and  fam222ba mutant zebrafish line, transcrip-
tion activator-like effector nuclease (TALEN)-mediated genome 
editing was performed as described elsewhere [van Impel et al., 
2014]. TALEN sequences were identified in candidate genes using 
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TAL Effector Nucleotide Targeter 2.0 (https://tale-nt.cac.cornell.
edu/). TALEN binding sites in  fam222bb exon 3 were: TAL1 
5 ′ -TACCCACCTCAGGTCA-3 ′ , TAL2 5 ′ -TCTTGGCCATAGT-
CAAA-3 ′ . For  Fam222ba the TALEN recognition sites were placed 
in exon 2: TAL1 5 ′ -TGTTTCTACCTCAACCATTCC-3 ′ , TAL2 
5 ′ -GGGCTCCATCAGGGCCGGCA-3 ′ . Lines were outcrossed 
into a  Tg(kdrl:GFP) s843 / Tg(gata1:dsRed) sd2 background.
 Image Acquisition 
 For all imaging experiments, larvae were treated with 0.2 m M 
1-phenyl-2-thiocarbamide no later than 24 h after fertilization to 
prevent the formation of pigment in skin cells. Confocal imaging 
was performed on living embryos embedded in 0.8–1% low melt-
ing point agarose (Invitrogen – Thermo Fisher) with tricaine. Im-
aging of the vascular network was achieved using Leica SPE and 
SP7 microscopes. Images were visualized by ImageJ FIJI software 
(http://fiji.sc/Fiji) or Leica LAS AF software and processed with 
Adobe Photoshop CS5.1.
 In vitro Studies 
 Primary human umbilical vein endothelial cells (HUVECs) 
were transfected with small interfering RNA (siRNA s226861, Am-
bion – Thermo Fisher) (final concentration: 10 n M ) and 8 μl of 
oligofectamine (Invitrogen – Thermo Fisher) according to the 
manufacturer’s protocol. OPTI-MEM was replaced after 4 h by 
ECGM (PromoCell, Heidelberg, Germany) containing 10% FCS. 
Total RNA was extracted using PeqGold (Peqlab – VWR, Radnor, 
Pa., USA) reagent and purified using Absolutely RNA Miniprep 
Kit (Agilent Technologies). Reverse transcription was done with 
First Strand cDNA Synthesis Kit (Thermo Fisher) and knockdown 
was assessed using the QuantStudio 3D Digital PCR System 
(LifeTechnologies – Thermo Fisher) or the LightCycler480 instru-
ment (Roche, Rotkreuz, Swiss) with a specific Universal Probe Li-
brary Assay for  FAM222B (Roche, UPL #38, primer left: 
5 ′ -CCAGAACAGCTTGATGCAAA-3 ′ , primer right: 5 ′ -CATG-
GCCAGGCTCTGTTC-3 ′ ). For spheroid formation, the cells were 
harvested one day after transfection and cultured as hanging drops 
for another 24 h. After crop of the spheroids, they were embedded 
into a collagen matrix. Following polymerisation, they were stimu-
lated with basal medium or a medium containing 25 ng/ml VEGF 
or FGF2 growth factors. After 24 h, sprouting was terminated by 
adding 10% paraformaldehyde to the wells.
 Results 
 Identification of a Frameshift Mutation in FAM222B 
through Exome Analysis 
 To address the question of further genetic heterogene-
ity for CCMs, exome sequencing was performed for one 
familial (father and daughter) and 4 isolated cases ( fig. 1 A) 
that had remained mutation-negative for  CCM1–3  [Stahl 
et al., 2008]. Of note, all probands reported early disease 
onset with a mean age at manifestation of 10.8 years 
(ranging from 9 months to 23 years). Clinical symptoms 
varied but tended to be severe with refractory epilepsy 
(individual I) and significant neurological deficits be-
cause of recurrent bleedings (individual II, IV–VI).
A
F
B C D E
G
 Fig. 1.  A Probands that were analysed by 
whole exome sequencing. The daughter (I) 
experienced complex focal epilepsy, where-
as her father (II) presented with headaches, 
focal epilepsy, and right-sided hemiparesis. 
The boy (III) reported recurrent head-
aches. Brain MRI of his parents did not 
show any lesions. The girl (IV) presented 
with acute strabismus, facial nerve paraly-
sis and headaches. Proband V presented 
with severe psychomotor retardation and 
paraplegia during early childhood. Pro-
band VI has multiple cerebral and spinal 
CCMs resulting in paraplegia after intra-
medullary bleeding. The age of onset is giv-
en next to the probands in years. Axial
( B–D ) and coronal ( E ) MRI of proband I. 
T2- (B), FLAIR- (C), (GRE) T2*- (D),
and T1-weighted (E) gadolinium-enhanced 
MRI of patient I who presented with sei-
zures at 5 years of age. Arrowheads indicate 
the cavernous lesion. Wild-type ( F ) and 
mutant ( G ) sequences of the variant in 
 FAM222B identified during WES in affect-
ed probands I and II. 
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 Whole exome sequencing of DNA from these patients 
led to  ∼ 210,000 variants in total. Bioinformatic filtering 
following the overlap strategy [Gilissen et al., 2012] re-
sulted in only 1 compelling candidate gene,  FAM222B 
( C17orf63 ), harbouring a Sanger-validated 2-bp deletion, 
c.1651_1652delAG (p.Arg552Lysfs * 10), which segrega t-
ed with CCMs within the family ( fig. 1 A, individuals I and 
II), but was not observed in any of the other 4 isolated 
cases. The second exome analyses with higher coverage 
again revealed the known FAM222B  frameshift mutation 
as the only compelling  candidate.
 Among the 6,503 controls from the NHLBI GO Exome 
Sequencing Project (EVS, Version v.0.0.14; http://evs.
gs.washington.edu/EVS/), no LOF mutation was found 
in  FAM222B which consists of 1 non-coding and 2 coding 
exons with the ATG initiator codon located in the second 
exon ( fig. 2 ). Sanger sequencing of the entire coding re-
gion and adjacent splice sites of  FAM222B was performed 
for 15 further  CCM1–3 mutation-negative probands 
[Spiegler et al., 2014]. However, this did not reveal a se c-
ond CCM individual carrying a  FAM222B LOF or likely 
pathogenic missense mutation. Since the additional CCM 
individuals tested were mainly isolated cases with disease 
onset later in life (ranging from 12 to 59 years), the lack-
ing genetic verification of  FAM222B may not only be due 
to genetic heterogeneity, but also to phenocopies or so-
matic mosaicism [McDonald et al., 2014; Lodato et al., 
2015].
 Yeast 2-Hybrid Interactors of FAM222B Are 
Components of the Cytoskeleton and the RAS-MAPK 
and PI3K/AKT/mTOR Pathways 
 FAM222B encodes for a widely expressed 60 kDa pro-
tein of thus far unknown function (Multi-Omics Profil-
ing Expression Database, PaxDb, The Human Protein At-
las). In silico analyses indicated the absence of a signal 
peptide, transmembrane domain or membrane anchor. 
In order to get a first idea on its putative roles, a human 
fetal brain cDNA library was screened using full-length 
human FAM222B as a bait in a LexA-based yeast 2-hy-
brid system. The most confident binding partners of 
FAM222B are listed in online supplementary table 1 (see 
www.karger.com/doi/10.1159/000446884, for all online 
suppl. material) and can be grouped into cytoskeletal 
components and proteins that are involved in different 
signalling cascades. In particular, the putative interac-
tions of FAM222B with the tubulin cytoskeleton (TUBB, 
TUBB2A, TUBB2B, and TUBA1B) represented a possible 
link to subcellular localisation and function of known 
CCM proteins. Of note, CCM1 has been suggested to be 
a microtubule-associated protein [Gunel et al., 2002; 
Béraud-Dufour et al., 2007; Fisher and Boggon, 2014]. 
Another interactor of FAM222B,  STAM -binding protein 
(STAMBP), has been described as a microtubule-associ-
ated protein involved in endosomal sorting of ubiquiti-
nated proteins [Tsang et al., 2006; McDonell et al., 2013]. 
Mutations in  STAMBP are associated with microcephaly-
capillary malformation syndrome and also cause dysre g-
 Fig. 2. Genomic organisation of human  FAM222B and zebrafish 
orthologues  fam222bb and  fam222ba . Exons are shown as boxes, 
introns as thin lines, lengths are given in bp. Coding parts are high-
lighted in dark blue, non-coding in light blue. ENSEMBL tran-
scripts are ENST00000581407 for human  FAM222B , ENSD-
ART00000154504 for zebrafish  fam222bb , and ENSD-
ART00000145247 for zebrafish  fam222ba . The 2-bp deletion 
identified in probands I and II is delineated by a red triangle. List-
ed LOF mutations from the ExAC browser are represented by red 
arrows. The binding site of the siRNA used for in vitro knockdown 
of  FAM222B is highlighted as a blue bar. Binding sites of TALE 
nucleases are shown as grey bars and the red flashes indicate the 
region where the mutagenesis took place. 
 Spiegler   et al.
 
 Mol Syndromol 2016;7:144–152 
DOI: 10.1159/000446884
148
ulation of the RAS-MAPK and PI3K/AKT/mTOR path-
ways [McDonell et al., 2013]. This suggested that 
FAM222B may act in concert with the known CCM pro-
teins in common networks.
 TALEN-Generated fam222bb/fam222ba Double 
Mutants Display Normal Vascular Morphology 
 Large-scale forward genetic screens have identified a 
characteristic cardiovascular phenotype in zebrafish car-
rying mutations in either  ccm1 ( santa ) or  ccm2  ( valen-
tine ) [Chen et al., 1996; Stainier et al., 1996; Mably et al., 
2006; Hogan et al., 2008]. At 2–4 days after fertilisation, 
this phenotype mainly consists of dilated, slowly con-
tracting heart chambers, disturbed blood circulation and 
pericardial edema, disorganised sprouting of subintesti-
nal vessels, and an enlarged caudal vein which is spatially 
barely distinguishable from the caudal artery. All these 
features could later be reproduced by simultaneous 
knockdown of  ccm3a and its duplicate  ccm3b using anti-
sense morpholino oligomers [Voss et al., 2009]. However, 
since these oligomers are known to often have off-target 
effects [Kok et al., 2015], we intended to analyse the ef-
fects of a  fam222b knockout in mutant zebrafish embryos 
generated by TALENs ( fig. 2 ). First, a founder fish bear-
ing a 10-bp deletion was selected since this frameshift
mutation in the  fam222bb gene ( fam222bb hu10539 ) is ex-
pected to result in protein truncation or nonsense-medi-
ated decay. Then, the founder fish was crossed with
 Tg(kdrl:GFP) s843 / Tg(gata1:dsRed) sd2 transgenic zebrafish 
in order to be able to visualise vascular morphology. Ho-
mozygous mutant, heterozygous and wild-type progeny 
was detected at the expected ratios, but no overt pheno-
type could be seen in embryos until 5 days after fertilisa-
tion.
 In 2013, a new update of the zebrafish reference ge-
nome assembly (Zv9) revealed the existence of a  fam222bb 
duplicate,  fam222ba . Thus, a double mutant line was gen-
erated carrying a 10-bp deletion in the  fam222ba gene 
 (fam222ba hu10755 ) in addition to the above-mentioned 
 fam222bb hu10539 mutation. However, homozygous dou-
ble mutants, 7 out of 59 analysed, were again indistin-
guishable from wild-type siblings 5 days after fertilisation 
( fig. 3 ). In addition, homozygous double mutants were 
viable to adulthood.
 Normal Sprouting of HUVECs after siRNA-Mediated 
Knockdown of FAM222B 
 Silencing of either  CCM1 or  CCM3 had been shown to 
induce sprouting angiogenesis in vitro  [Wüstehube et al., 





 Fig. 3.  fam222bb  and  fam222ba double 
mutants display no CCM-specific vascu-
lar phenotype.  A Schematic of Fam222bb 
and Fam222ba domain structure, indicat-
ing the position of  fam222bb hu10539  and
 fam222ba hu10755 amino acid frameshifts 
and premature stop mutations (red bars). 
FAM222A: domain of unknown function. 
Examples of sequencing reads of  fam222bb 
( B ) and  fam222ba ( C ) wild-type, heterozy-
gous and homozygous zebrafish embryos; 
the respective 10-bp deletion is marked
in the wild-type read.  D Brightfield pic-
ture and confocal micrograph of 3 dpf 
 fam222bb/fam222ba double mutant ze-
brafish trunk bearing Tg (kdrl:egfp) s843 
(green). 
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specific siRNA was used to knock down  FAM222B ( fig. 2 ) 
in HUVECs and to study the corresponding in vitro an-
giogenic phenotype in a 3D, spheroid-based sprouting as-
say as previously described [Korff and Augustin, 1998; 
Heiss et al., 2015]. Although  FAM222B expression of
siRNA-treated HUVECs was efficiently downregulated, 
no activation of angiogenic sprouting could be observed 
( fig. 4 ). Neither length nor number of sprouts were sig-
nificantly altered in  FAM222B knockdown spheroids 
upon stimulation with VEGF or FGF2. These observa-
tions were in line with the lack of a vascular phenotype in 
 fam222bb  hu10539 / fam222ba hu10755  double mutant zebra-
fish and strengthened the assumption that  FAM222B is 
not involved in pathways keeping endothelial cells quies-
cent.
 Discussion 
 The identification of inactivating mutations in  CCM1 , 
 CCM2 , and  CCM3 in individuals affected with CCM led 
to the insight that the 3 gene products contribute to regu-
late angiogenesis and to maintain vascular homeostasis. 
Similarly, the association of a  FAM222B frameshift muta-
tion with early disease manifestation in an affected daugh-
ter and her father had raised the hope that this gene of 
thus far unknown function might be essential for vascular 
morphogenesis and integrity. However, despite the re-
cent observation that deleterious mutations may activate 
compensatory networks in zebrafish [Rossi et al., 2015], 
our experimental studies using in vitro and in vivo angio-
genesis model systems suggest that FAM222B is not re-
quired for vasculogenesis and angiogenesis.
 During the course of our experiments, the Exome Ag-
gregation Consortium (ExAC) database was published, 
which comprises 60,706 exomes from individuals not af-
Table 1.  Absolute numbers of LOF mutations in the known CCM and FAM222B genes as listed in the ExAC browser
Gene Nonsense Frameshift Splice Total HGMD Overlapping EVS
CCM1 6 7 (6) 3 15 (14) 6 2 (1× fs, 1× nonsense) 2
CCM2 1 0 2 3 1 2 (splice site) 0
CCM3 0 0 0 0 0 0 0
FAM222B 5 (2) 8 (5) 0 13 (7) – – 0
 The number of unique LOF mutations is given in brackets. The column HGMD indicates the number of mutations listed as disease 
causing in the HGMD database, another mutation at the same position is classified as overlapping (source: HGMD® Professional data-
base 2015.4). The column EVS specifies the number of LOF mutations included in the Exome Variant Database (http://evs.gs.
washington.edu/EVS/). None of them are listed in the HGMD database. fs = Frameshift.
 Fig. 4. Spheroid sprouting of HUVECs transfected with negative 
control siRNA and siRNA against  FAM222B . Top row: after trans-
fection ,  HUVEC spheroids were embedded in a collagen matrix 
under basal condition and with addition of 25 ng/ml VEGF or 
FGF2 growth factors. Middle row: transfection of HUVEC with 
siRNA against  FAM222B led to  ∼ 85% mRNA knockdown rates 
compared to non-silencing control siRNA. Bottom: average sprout 
length and number of sprouts per spheroid are not significantly 
altered between control conditions and  FAM222B knockdown.
n = 4 experiments. Scale bar = 50 μm. Bar graphs depict mean val-
ues, error bars show standard error of the mean. 
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fected by severe paediatric diseases. While no  FAM222B 
LOF mutation was found in 6,503 controls from the EVS 
at the time the exome analyses had been performed,
13 heterozygous  FAM222B LOF mutations were later 
found in the ExAC database. The 2-bp deletion 
c.1651_1652delAG which segregated with CCM in the 
familial case is listed 3 times in ExAC (Cambridge, Mass., 
Version 0.3/ 02/2016, http://exac.broadinstitute.org/) 
( table 1 ).
 Therefore, we reviewed the ExAC database for LOF 
mutations in the known  CCM1–3 genes ( table 1 ): it is re-
markable that 6 of the 15 LOF mutations within  CCM1 
and 1 of 3 LOF mutations within  CCM2 have been de-
scribed as disease causing in the HGMD database 
(HGMD ® Professional database 2015.4; online suppl. 
table 2). This fact may be reconciled with the observation 
that disease penetrance is age-dependent and incomplete 
and disease manifestation variable for CCM. Notably,
asymptomatic carrier parents harbouring at least one 
CCM have been observed in 75% of ‘apparently sporadic 
index cases with multiple lesions’ [Labauge et al., 1998], 
while bona fide de novo mutations have only rarely been 
documented for  CCM1  [Stahl et al., 2008] and  CCM3 
 [Bergametti et al., 2005]. In contrast to  CCM1 and CCM2 , 
not a single LOF mutation within  CCM3 is mentioned in 
the ExAC database. This may be in line with the observa-
tion that 50–53% of index cases carrying a  CCM3 muta-
tion became symptomatic prior to age 15 – mostly with 
early-onset cerebral haemorrhages [Denier et al., 2006; 
Spiegler et al., 2014; Shenkar et al., 2015].
 For the exome study presented here, we selected af-
fected individuals with early and rather severe disease on-
set in order to search for a putative fourth causative gene 
in the remaining 13–43% of  CCM1–3 mutation-negative 
probands. Thus, a bioinformatic filtering process consi d-
ering the ExAC data may orientate towards the  CCM2 
and  CCM3 data in ExAC and rather not allow more than 
3 LOF mutations within the same gene and no recurrence 
for exactly the same mutation. On the one hand, our ex-
perimental data seem to support such strict filter criteria. 
On the other hand,  CCM1 would have been excluded. 
Therefore, filter criteria need to be individually adapted 
even within one genetically heterogeneous condition [Al-
bers et al., 2012], and a small number of occurrences in 
ExAC may not disqualify a candidate gene.
 The advent of the ExAC database also prompted us to 
review disease prevalence of  CCM1–3 LOF mutations. 
Based on the ExAC data, 1 in 3,373 individuals that do 
not display a severe paediatric disease harbour an inacti-
vating heterozygous  CCM1 or  CCM2 germline mutation. 
Given that almost all  CCM mutation carriers reveal at 
least one cavernous lesion if high-resolution MRI is per-
formed [Denier et al., 2006], one can assume that the car-
riers of the 18 LOF  CCM1–2 mutations listed in the 
ExAC database ( table 1 ) bear asymptomatic CCMs that 
would have been detected in high-resolution MRI or au-
topsy study series. These had revealed that CCM occurs 
with a prevalence of about 0.5%/1: 185–1: 255 in hospital-
based series [Del Curling et al., 1991; Robinson et al., 
1991] and autopsies [Otten et al., 1989]. For neurologi-
cally asymptomatic people, the prevalence is lower and 
has been reported to be about 0.15%/1: 676 [Morris et al., 
2009] in a large meta-analysis. A recent prospective, pop-
ulation-based cohort study also pointed out that 24 of 
139 (i.e., 17%) adults with CCMs had multiple lesions 
[Al-Shahi Salman et al., 2012]. In conclusion, the ExAC 
data most likely reflect the frequency of asymptomatic 
familial cases carrying  CCM1 and  CCM2 mutations and 
are in agreement with the previously published assump-
tion that close to 20% of Caucasians that carry at least one 
CCM are in fact familial [Denier et al., 2006; Fischer et 
al., 2013]. 
 Conclusion 
 Taken together, our experimental results as well as the 
ExAC data,  FAM222B variants would currently not qual-
ify to be used for predictive genetic testing of relatives. 
Even with high-throughput sequencing techniques, it re-
mains challenging to identify unambiguously disease-
causing mutations in a novel gene for a genetically het-
erogeneous condition with incomplete penetrance and 
variable clinical manifestations such as CCM. A further 
major obstacle is the likely occurrence of somatic muta-
tions in a proportion of isolated CCM cases with multiple 
lesions but  CCM1–3 mutation negativity in lymphocytes.
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